These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2700694)

  • 1. [Clinical study on the treatment of dyskinesia by L-stepholidine].
    Le W
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Dec; 22(6):335-7, 381-2. PubMed ID: 2700694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A controlled study on the treatment of tardive dyskinesia using 1-stepholidine].
    Cai N
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):281-3, 319. PubMed ID: 3069384
    [No Abstract]   [Full Text] [Related]  

  • 3. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications.
    Mo J; Guo Y; Yang YS; Shen JS; Jin GZ; Zhen X
    Curr Med Chem; 2007; 14(28):2996-3002. PubMed ID: 18220736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
    Stahl SM; Thornton JE; Simpson ML; Berger PA; Napoliello MJ
    Biol Psychiatry; 1985 Aug; 20(8):888-93. PubMed ID: 3861199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cases of abnormal movements].
    Singer B
    Sem Hop; 1979 Jan 8-15; 55(1-2):83-4. PubMed ID: 34219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The trial use of clozapine for abnormal involuntary movement disorders.
    Caine ED; Polinsky RJ; Kartzinel R; Ebert MH
    Am J Psychiatry; 1979 Mar; 136(3):317-20. PubMed ID: 154301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [1-SPD, a new dopamine receptors blocker, in treating vascular headache].
    Le WD; Zhou XD; Wang WJ
    Zhonghua Nei Ke Za Zhi; 1987 Dec; 26(12):681-4, 741. PubMed ID: 3451849
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal involuntary movements: a study of dopaminergic receptor interaction.
    Agnoli A; Ruggieri S; Del Roscio S; Baldassarre M; Bocola V; Denaro A
    Adv Neurol; 1983; 37():305-12. PubMed ID: 6858777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H; Sabouraud O
    Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Feed-back regulation of presynaptic D2 receptors blockaded by l-stepholidine and l-tetrahydropalmatine].
    Chen LJ; Guo X; Wang QM; Jin GZ
    Zhongguo Yao Li Xue Bao; 1992 Sep; 13(5):442-5. PubMed ID: 1300050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine therapy for tardive dyskinesia and related syndromes.
    Nishikawa T; Tanaka M; Tsuda A; Koga I; Uchida Y
    Clin Neuropharmacol; 1984; 7(3):239-45. PubMed ID: 6488198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction.
    Chu H; Jin G; Friedman E; Zhen X
    Cell Mol Neurobiol; 2008 Jun; 28(4):491-9. PubMed ID: 17710533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Cenci MA
    Trends Neurosci; 2007 May; 30(5):236-43. PubMed ID: 17400300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.